Ensysce Biosciences, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Ensysce amended its Series C Non-Voting Convertible Preferred Stock certificate of designation on September 24, 2026. The Board approved the amendment on September 17, 2026, and Series C holders consented on September 23, 2026. The amendment deleted Section 6.5.3 in its entirety and removed related references from Sections 6.2, 6.5.4, and 8 of the certificate, replacing the deleted section with '[Reserved].' The filing does not disclose what Section 6.5.3 contained or what economic or rights impact this deletion has.
Why this rating
Technical amendment to preferred stock terms; specifics of deleted provision undisclosed. Cannot assess true impact without knowing what rights were removed. No dollar amounts or share conversion terms disclosed.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.